Safety fears wipe billions off drug shares
Richard Wray and Charlotte Moore
Saturday December 18, 2004
Source The Guardian
More than $31bn (£16bn) was yesterday knocked off the value of Pfizer, the world's largest pharmaceutical company and maker of Viagra, after doubts surfaced over the safety of one of its key drugs.
The revelation comes only weeks after rival Merck decided to withdraw its painkiller Vioxx, from the same family of drugs, because of similar fears about side- effects.
News that one of Pfizer's main drugs, Celebrex, used to combat arthritis and available on prescription in the
There had been hopes that the drug offered a breakthrough in cancer treatment, but a study of just under 1,700 patients showed that it appeared to have no significant life-prolonging effects.
The blow follows recent news that AstraZeneca's drug, Exanta, used to treat strokes, had been blocked by the
In New York Pfizer's shares plummeted after it said trials of Celebrex as a treatment for cancer rather than arthritis showed it more than doubled the risk of heart problems.
Celebrex, which is available in the
Celebrex and Vioxx are anti-inflammatories and were launched in the
New York-based Pfizer said yesterday that a trial carried out by the National Cancer Institute into the use of Celebrex to treat cancerous tumours, was halted after results showed "an approximately 2.5-fold increase" in the risk of non-fatal heart attacks in patients.
The company stressed, however, that a second trial investigating whether the drug could prevent intestinal growths did not reveal any link between Celebrex and heart attacks. Adverse findings in a similar trial caused Merck to withdraw Vioxx.
Campaigners yesterday said the European Medicines Agency was reviewing data on the potential cardiovascular effects of Cox-2 inhibitors. The US Food and Drug Administration said it had "great concerns" about Celebrex and other Cox-2 inhibitors, acting FDA commissioner Lester Crawford said last night. A statement from the FDA is likely in the next few days.
The latest news may worry patients.” The withdrawal of Vioxx on the grounds that it increased the risk of heart attack and stroke, makes this news from Pfizer that there might be similar problems with Celebrex worrying," said a spokeswoman for the Arthritis Research Campaign.
But she stressed: "There has never been any suggestion from previous data that Celebrex may increase the risk of heart problems and current prescribing advice is that Cox-2s should not be given to those arthritis patients at risk of heart attack or stroke."
A spokesman for Pfizer said the company had no plans to take the drug off the market.
Hank McKinnell, chairman and chief executive of Pfizer, said: "The cardiovascular findings in one of the studies are unexpected and not consistent with the reported findings in the second study."
Comments
your voice counts
There are currently no comments on this post.
Your voice counts
We welcome your comments and are very interested in your point of view, but we ask that you keep them relevant to the article, that they be civil and without commercial links. All comments are moderated prior to being published. We reserve the right to edit or not publish comments that we consider abusive or offensive.
There is extra content here from a third party provider. You will be unable to see this content unless you agree to allow Content Cookies. Cookie Preferences